Minsig Choi, MD
Medical Oncology · Edgewood, KYNPI 1073629812
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $238,256 of the $348,301 with a category attached, or 68.4%. 37 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.5% of the total. Among medical oncology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $967.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$141K
- Genentech USA, Inc.$39K
- Ipsen Biopharmaceuticals, Inc$29K
- Eisai Inc.$21K
- Exelixis Inc.$20K
- Amgen$16K
- plus $82K from 31 others
Across 95 payments — averaging $16,446 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$1M
- Merck$258K
- Ipsen Bioscience Inc.$237K
- Amgen$37K
- AstraZeneca$23K
- Bausch Health US, LLC$4K
- plus $339 from 1 others
What the payments were for
- Consulting fees$55,32816%
- Speaking & faculty fees$238,25668%
- Travel & lodging$41,88912%
- Food & beverage$12,8174%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 105 | $141,046 |
| Genentech USA, Inc. | 30 | $39,326 |
| Ipsen Biopharmaceuticals, Inc | 27 | $28,960 |
| Eisai Inc. | 18 | $20,915 |
| Exelixis Inc. | 21 | $19,729 |
| Amgen | 18 | $16,094 |
| Lilly USA, LLC | 26 | $15,750 |
| Bayer | 23 | $12,403 |
| Merck | 19 | $7,446 |
| Deciphera Pharmaceuticals Inc. | 9 | $7,385 |
| Gilead | 8 | $5,305 |
| Bristol Myers Squibb | 4 | $5,093 |
| AstraZeneca | 8 | $4,415 |
| Avyxa Pharma, LLC | 7 | $4,072 |
| Jazz Pharmaceuticals Inc. | 2 | $3,399 |
| Astellas Pharma US Inc | 1 | $3,000 |
| Astellas Pharma Global Development | 1 | $2,704 |
| Taiho Oncology, Inc. | 3 | $2,413 |
| Novartis | 3 | $2,153 |
| Advanced Accelerator Applications | 2 | $2,086 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,040 |
| Tempus AI, Inc | 5 | $480 |
| Inari Medical, Inc. | 2 | $368 |
| Incyte Corporation | 2 | $259 |
| Histosonics, Inc. | 1 | $259 |
| Daiichi Sankyo Inc. | 1 | $200 |
| Steris Corporation | 1 | $150 |
| Progenics Pharmaceuticals, Inc. | 1 | $132 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $125 |
| AbbVie | 1 | $125 |
| Boston Scientific | 2 | $125 |
| Coherus Oncology, Inc. | 1 | $107 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $106 |
| Aimmune Therapeutics, Inc. | 1 | $65 |
| Array Biopharma Inc | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $24 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$116,782
- TECENTRIQ$35,503
- ONIVYDE$28,339
- LENVIMA$22,224
- Cabometyx$19,247
- Vectibix$16,013
- CYRAMZA$15,750
- Stivarga$10,267
- QINLOCK$7,179
- Nexavar$5,501
- Abraxane$5,093
- Lutathera$4,111
- ZIIHERA$3,399
- Vyloy$2,704
- Lonsurf$2,340
- FRUZAQLA$2,040
- IMFINZI$767
- LYNPARZA$525
- FLOWTRIEVER CATHETER, S$368
- CT THROMBECTOMY SYSTEM KIT$368
How this compares
$348,301 in reported general payments places this provider in the 95th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $23,741 |
| CreonLipase/Protease/Amylase | 20 | $19,569 |
| Imatinib Mesylate | 19 | $1,627 |
| Dexamethasone | 76 | $1,536 |
| Prochlorperazine Maleate | 111 | $1,384 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 43 | $589 |
| Oxycodone Hcl | 35 | $411 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $406 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $183 |
| Pantoprazole Sodium | 17 | $180 |
| Potassium Chloride | 15 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $125 | $19,56920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Edgewood
- Matthew KurianEdgewood$47K
- Douglas FloraEdgewood$20K
- Lawrence BrennanEdgewood$3K
- Manish BhandariEdgewood$1K
- Mary Redden BorowskiEdgewood$675
- Christy SappEdgewood$466
- David MoskoEdgewood$223
- William DannemanEdgewood$47
- Lowell AnthonyLexington$55K
- Jewraj MaheshwariOwensboro$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.